Rational design of dualsteric GPCR ligands: Quests and promise

British Journal of Pharmacology

Volumn 159, Issue 5, 2010, Pages 997-1008

  Mohr, Klaus ^a   Tränkle, Christian ^a   Kostenis, Evi ^a   Barocelli, Elisabetta ^b   De Amici, Marco ^c   Holzgrabe, Ulrike ^d  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF PARMA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Allosteric; Bitopic; Dualsteric; Functional selectivity; G protein coupled receptors; Multivalent; Muscarinic acetylcholine receptor; Orthosteric; Subtype selectivity

Indexed keywords

G PROTEIN COUPLED RECEPTOR; LIGAND; MUSCARINIC AGENT; MUSCARINIC RECEPTOR; PIRENZEPINE;

ALLOSTERISM; BINDING AFFINITY; BINDING SITE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; THERMODYNAMICS; VALIDATION STUDY;

ALLOSTERIC SITE; ANIMALS; BINDING SITES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; LIGANDS; PROTEIN BINDING; RECEPTORS, G-PROTEIN-COUPLED;

EID: 77949409939     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00601.x     Document Type: Review

References (81)

1. Alexander SPH, Mathie A, Peters JA (2008). Guide to receptors and channels (GRAC), 3rd edition (2008 revision). Br J Pharmacol 153 (Suppl. 2): S1-S209.
2. Antony J, Kellershohn K, Mohr-Andrä M, Kebig A, Prilla S, Muth M et al. (2009). Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity. FASEB J 23: 442-450.
3. Avlani VA, Gregory KJ, Morton CJ, Parker MW, Sexton PM, Christopoulos A (2007). Critical role for the second extracellular loop in the binding of both orthosteric and allosteric G protein-coupled receptor ligands. J Biol Chem 282: 25677-25686.
4. Ballesteros JA, Weinstein H (1995). Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci 25: 366-428.
5. Birdsall NJ, Lazareno S (2005). Allosterism at muscarinic receptors: ligands and mechanisms. Mini Rev Med Chem 5: 523-543.
6. Birdsall NJ, Burgen AS, Hulme EC, Stockton JM, Zigmond MJ (1983). The effect of McN-A-343 on muscarinic receptors in the cerebral cortex and heart. Br J Pharmacol. 78: 257-259.
7. Bonner TI, Buckley NJ, Young AC, Brann MR (1987). Identification of a family of muscarinic acetylcholine receptor genes. Science 237: 527-532.
8. Buller S, Zlotos DP, Mohr K, Ellis J (2002). Allosteric site on muscarinic acetylcholine receptors: a single amino acid in transmembrane region 7 is critical to the subtype selectivities of caracurine V derivatives and alkane-bisammonium ligands. Mol Pharmacol 61: 160-168.
9. Chung S, Funakoshi T, Civelli O (2008). Orphan GPCR research. Br J Pharmacol 153 (Suppl. 1): S339-346.
10. Clark AL, Mitchelson F (1976). The inhibitory effect of gallamine on muscarinic receptors. Br J Pharmacol 58: 323-331.
11. Conn PJ, Christopoulos A, Lindsley CW (2009). Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nature Rev Drug Discov 8: 41-54.
12. Dallanoce C, Conti P, De Amici M, De Micheli C, Barocelli E, Chiavarini M et al. (1999). Synthesis and functional characterization of novel derivatives related to oxotremorine and oxotremorine-M. Bioorg Med Chem 7: 1539-1547.
13. De Amici M, Dallanoce C, Tränkle C, Holzgrabe U, Mohr K (2009). Allosteric ligands for G protein-coupled receptors: a novel strategy with attractive therapeutic opportunities. Med Res Rev in press (DOI 10.1002/Med).
14. Disingrini T, Muth M, Dallanoce C, Barocelli E, Bertoni S, Kellershohn K et al. (2006). Design, synthesis, and action of oxotremorinerelated hybrid-type allosteric modulators of muscarinic acetylcholine receptors. J Med Chem 49: 366-372.
15. Eberlein WG, Engel W, Mihm G, Rudolf K,Wetzel B, EntzerothMet al. (1989). Structure-activity relationships and pharmacological profile of selective tricyclic antimuscarinics. Trends Pharmacol Sci (Suppl.): 50-54.
16. Ellis J, Seidenberg M, Brann MR (1993). Use of chimeric muscarinic receptors to investigate epitopes involved in allosteric interactions. Mol Pharmacol 44: 583-588.
17. Ellis J, Huyler J, Brann MR (1991). Allosteric regulation of cloned m1-m5 muscarinic receptor subtypes. Biochem Pharmacol 42: 1927-1932.
18. Ellis J, Seidenberg M (2000). Interactions of alcuronium, TMB-8, and other allosteric ligands with muscarinic acetylcholine receptors: studies with chimeric receptors. Mol Pharmacol 58: 1451-1460.
19. Engel WW, Eberlein WG, Mihm G, Hammer R, Trummlitz G (1989). Tricyclic compounds as selective muscarinic receptor antagonists. 3. Structure-selectivity relationships in a series of cardioselective (M2) antimuscarinics. J Med Chem 32: 1718-1724.
20. Entzeroth M, Mayer N (1990). Labeling of rat heart muscarinic receptors using the new M2 selective antagonist [3H]AF-DX 384. Biochem Pharmacol 40: 1674-1676.
21. Fozard JR, Muscholl E (1971). Effects of several muscarinic agonists on cardiac performance and the release of noradrenaline from the sympathetic nerves of the rabbit heart. Br J Pharmacol 43: 454P-455P.
22. Gao ZG, Jacobson KA (2006). Allosterism in membrane receptors. Drug Discov and Today 11: 191-202.
23. Giraldo E, Micheletti R, Montagna E, Giachetti A, Viganò MA, Ladinsky H et al. (1988). Binding and functional characterization of the cardioselective muscarinic antagonist methoctramine. J Pharmacol Exp Ther 244: 1016-1020.
24. Gnagey A, Ellis J (1996). Allosteric regulation of the binding of [3H]acetylcholine to m2 muscarinic receptors. Biochem Pharmacol 52: 1767-1775.
25. Gnagey AL, Seidenberg M, Ellis J (1999). Site-directed mutagenesis reveals two epitopes involved in the subtype selectivity of the allosteric interactions of gallamine at muscarinic acetylcholine receptors. Mol Pharmacol 56: 1245-1253.
26. Goin JC, Leiros CP, Borda E, Sterin-Borda L (1997). Interaction of human chagasic IgG with the second extracellular loop of the Hum heart muscarinic acetylcholine receptor: functional and pathological implications. FASEB J 11: 77-83.
27. Grossmüller M, Antony J, Tränkle C, Holzgrabe U, Mohr K (2006). Allosteric site in M2 acetylcholine receptors: evidence for a major conformational change upon binding of an orthosteric agonist instead of an antagonist. Naunyn Schmiedebergs Arch Pharmacol 372: 267-276.
28. Hammer R, Berrie CP, Birdsall NJ, Burgen AS, Hulme EC (1980). Pirenzepine distinguishes between different subclasses of muscarinic receptors. Nature 283: 90-92.
29. Heilker R, Wolff M, Tautermann CS, Bieler M (2009). G-proteincoupled receptor-focused drug discovery using a target class platform approach. Drug Discov and Today 14: 231-240.
30. Hernandez CC, Nascimento JH, Chaves EA, Costa PC, Masuda MO, Kurtenbach E et al. (2008). Autoantibodies enhance agonist action and binding to cardiac muscarinic receptors in chronic Chagas' disease. J Recept Signal Transduct 28: 375-401.
31. Hoffmann C, Zürn A, Bünemann M, Lohse MJ (2008). Conformational changes in G-protein-coupled receptors-the quest for functionally selective conformations is open. Br J Pharmacol 153 (Suppl. 1): S358-366.
32. Huang XP, Ellis J (2007). Mutational disruption of a conserved disulfide bond in muscarinic acetylcholine receptors attenuates positive homotropic cooperativity between multiple allosteric sites and has subtype-dependent effects on the affinities of muscarinic allosteric ligands. Mol Pharmacol 71: 759-768.
33. Huang XP, Prilla S, Mohr K, Ellis J (2005). Critical amino acid residues of the common allosteric site on the M2 muscarinic acetylcholine receptor: more similarities than differences between the structurally divergent agents gallamine and bis(ammonio)alkane-type hexamethylene-bis-[dimethyl-(3- phthalimidopropyl)ammonium]d ibromide. Mol Pharmacol 68: 769-778.
34. Jäger D, Schmalenbach C, Prilla S, Kebig A, Sennwitz M, Heller E et al. (2007). Allosteric small molecules unveil a role of an extracellular E2/transmembrane helix 7 junction for G protein-coupled receptor activation. J Biol Chem 282: 34968-34976.
35. Jakubík J, Tuček S (1994). Protection by alcuronium of muscarinic receptors against chemical inactivation and location of the allosteric binding site for alcuronium. J Neurochem 63: 1932-1940.
36. Jakubík J, Bacáková L, El-Fakahany EE, Tuček S (1997). Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol 52: 172-179.
37. Jakubík J, Krejcí A, Dolezal V (2005). Asparagine, valine, and threonine in the third extracellular loop of muscarinic receptor have essential roles in the positive cooperativity of strychnine-like allosteric modulators. J Pharmacol Exp Ther 313: 688-696.
38. Jepsen K, Lüllmann H, Mohr K, Pfeffer J (1988). Allosteric stabilization of [3H]N-methylscopolamine binding in guinea-pig myocardium by an antidote against organophosphate intoxication. Pharmacol Toxicol 63: 163-168.
39. Jöhren K, Höltje HD (2002). A model of the human M2 muscarinic acetylcholine receptor. J Comput Aided Mol Des 16: 795-801.
40. Kebig A, Kostenis E, Mohr K, Mohr-Andrä M (2009). An optical dynamic mass redistribution assay reveals biased signaling of dualsteric GPCR activators, J. Recept Signal Transduct 29: 140-145.
41. Kobilka BK, Deupi X (2007). Conformational complexity of G-proteincoupled receptors. Trends Pharmacol Sci 28: 397-406.
42. Kostenis E, Mohr K (1996). Two-point kinetic experiments to quantify allosteric effects on radioligand dissociation. Trends Pharmacol Sci 17: 280-283.
43. Krejcí A, Tuček S (2001). Changes of cooperativity between N-methylscopolamine and allosteric modulators alcuronium and gallamine induced by mutations of external loops of muscarinic M(3) receptors. Mol Pharmacol 60: 761-767.
44. Kubo T, Fukuda K, Mikami A, Maeda A, Takahashi H, Mishina M et al. (1986). Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor. Nature 323: 411-416.
45. Lambrecht G, Moser U, Grimm U, Pfaff O, Hermanni U, Hildebrandt C et al. (1993). New functionally selective muscarinic agonists. Life Sci 52: 481-488.
46. Lanzafame A, Christopoulos A, Mitchelson F (2001). The allosteric interaction of otenzepad (AF-DX 116) at muscarinic M2 receptors in guinea pig atria. Eur J Pharmacol 416: 235-244.
47. Lazareno S, Gharagozloo P, Kuonen D, Popham A, Birdsall NJ (1998). Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: radioligand binding studies. Mol Pharmacol 53: 573-589.
48. Lee NH, El-Fakahany EE (1991). Allosteric interactions at the m1, m2 and m3 muscarinic receptor subtypes. J Pharmacol Exp Ther 256: 468-479.
49. Leppik RA, Miller RC, Eck M, Paquet JL (1994). Role of acidic amino acids in the allosteric modulation by gallamine of antagonist binding at the m2 muscarinic acetylcholine receptor. Mol Pharmacol 45: 983-990.
50. Leppik RA, Lazareno S, Mynett A, Birdsall NJ (1998). Characterization of the allosteric interactions between antagonists and amiloride analogues at the human a2A-adrenergic receptor. Mol Pharmacol 53: 916-925.
51. Lüllmann H, Ohnesorge FK, Schauwecker GC, Wassermann O (1969). Inhibition of the actions of carbachol and DFP on guinea pig isolated atria by alkane-bis-ammonium compounds. Eur J Pharmacol 6: 241-247.
52. Mammen M, Choi SK, Whitesides GM (1998). Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angewandte Chemie Int Ed 37: 2755-2794.
53. Matsui H, Lazareno S, Birdsall NJ (1995). Probing of the location of the allosteric site on m1 muscarinic receptors by site-directed mutagenesis. Mol Pharmacol 47: 88-98.
54. May LT, Leach K, Sexton PM, Christopoulos A (2007a). Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 47: 1-51.
55. May LT, Avlani VA, Langmead CJ, Herdon HJ, Wood MD, Sexton PM et al. (2007b). Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors. Mol Pharmacol 72: 463-476.
56. Melchiorre C, Cassinelli A, Quaglia W (1987a). Differential blockade of muscarinic receptor subtypes by polymethylene tetraamines. Novel class of selective antagonists of cardiac M-2 muscarinic receptors. J Med Chem 30: 201-204.
57. Melchiorre C, Angeli P, Lambrecht G, Mutschler E, Picchio MT, Wess J (1987b). Antimuscarinic action of methoctramine, a new cardioselective M-2 muscarinic receptor antagonist, alone and in combination with atropine and gallamine. Eur J Pharmacol 144: 117-124.
58. Melchiorre C, Minarini A, Angeli P, Giardinà D, Gulini U, Quaglia W (1989). Polymethylene tetraamines as muscarinic receptor probes. Trends Pharmacol Sci (Suppl.): 55-59.
59. Mohr K, Tränkle C, Holzgrabe U (2003). Structure/activity relationships of M2 muscarinic allosteric modulators. Receptors Channels 9: 229-240.
60. Mohr M, Heller E, Ataie A, Mohr K, Holzgrabe U (2004). Development of a new type of allosteric modulator of muscarinic receptors: hybrids of the antagonist AF-DX 384 and the hexamethonio derivative W84. J Med Chem 47: 3324-3327.
61. Nedoma J, Tuček S, Danilov AF, Shelkovnikov SA (1986). Stabilization of antagonist binding to cardiac muscarinic acetylcholine receptors by gallamine and other neuromuscular blocking drugs. J Pharmacol Exp Ther 236: 219-223.
62. Potter LT, Ferrendelli CA, Hanchett HE, Hollifield MA, Lorenzi MV (1989). Tetrahydroaminoacridine and other allosteric antagonists of hippocampal M1 muscarine receptors. Mol Pharmacol 35: 652-660.
63. 422Trp in a critical cluster of amino acids for baseline affinity, subtype selectivity, and cooperativity. Mol Pharmacol 70: 181-193.
64. Roffel AF, Elzinga CR, Meurs H, Zaagsma J (1989). Allosteric interactions of three muscarine antagonists at bovine tracheal smooth muscle and cardiac M2 receptors. Eur J Pharmacol 172: 61-70.
65. Rosenbaum DM, Rasmussen SG, Kobilka BK (2009). The structure and function of G-protein-coupled receptors. Nature 459: 356-363.
66. Roszkowski AP (1961). An unusual type of sympathetic ganglionic stimulant. J Pharmacol Exp Ther. 132: 156-170.
67. Schröter A, Tränkle C, Mohr K (2000). Modes of allosteric interactions with free and [3H]N-methylscopolamine-occupied muscarinic M2 receptors as deduced from buffer-dependent potency shifts. Naunyn Schmiedebergs Arch Pharmacol 362: 512-519.
68. Schwartz TW, Frimurer TM, Holst B, Rosenkilde MM, Elling CE (2006). Molecular mechanism of 7TM receptor activation - a global toggle switch model. Annu Rev Pharmacol Toxicol. 46: 481-519.
69. Steinfeld T, Mammen M, Smith JA, Wilson RD, Jasper JR (2007). A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor. Mol Pharmacol 72: 291-302.
70. Sterin-Borda L, Gorelik G, Borda ES (1991). Chagasic IgG binding with cardiac muscarinic cholinergic receptors modifies cholinergicmediated cellular transmembrane signals. Clin Immunol Immunopathol 61: 387-397.
71. Stockton JM, Birdsall NJ, Burgen AS, Hulme EC (1983). Modification of the binding properties of muscarinic receptors by gallamine. Mol Pharmacol 23: 551-557.
72. Tahtaoui C, Parrot I, Klotz P, Guillier F, Galzi JL, Hibert M et al. (2004). Fluorescent pirenzepine derivatives as potential bitopic ligands of the human M1 muscarinic receptor. J Med Chem 47: 4300-4315.
73. Tränkle C, Kostenis E, Burgmer U, Mohr K (1996). Search for lead structures to develop new allosteric modulators of muscarinic receptors. J Pharmacol Exp Ther 279: 926-933.
74. Tränkle C, Andresen I, Lambrecht G, Mohr K (1998). M2 receptor binding of the selective antagonist AF-DX 384: possible involvement of the common allosteric site. Mol Pharmacol 53: 304-312.
75. Tränkle C,Weyand O, Voigtländer U, Mynett A, Lazareno S, Birdsall NJ et al. (2003). Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors. Mol Pharmacol 64: 180-190.
76. Valant C, Gregory KJ, Hall NE, Scammells PJ, Lew MJ, Sexton PM et al. (2008). A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. J Biol Chem 283: 29312-29321.
77. Voigtländer U, Jöhren K, Mohr M, Raasch A, Tränkle C, Buller S et al. (2003). Allosteric site on muscarinic acetylcholine receptors: identification of two amino acids in the muscarinic M2 receptor that account entirely for the M2/M5 subtype selectivities of some structurally diverse allosteric ligands in N-methylscopolamine-occupied receptors. Mol Pharmacol 64: 21-31.
78. Waelbroeck M, Camus J, Tastenoy M, Christophe J (1992). Binding properties of nine 4-diphenyl-acetoxy-N-methyl-piperidine (4-DAMP) analogues to M1, M2, M3 and putative M4 muscarinic receptor subtypes. Br J Pharmacol 105: 97-102.
79. Wess J, Eglen RM, Gautam D (2007). Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov 6: 721-733.
80. Wess J, Han SJ, Kim SK, Jacobson KA, Li JH (2008). Conformational changes involved in G-protein-coupled-receptor activation. Trends Pharmacol Sci 29: 616-625.
81. Zahn K, Eckstein N, Tränkle C, Sadée W, Mohr K (2002). Allosteric modulation of muscarinic receptor signaling: alcuronium-induced conversion of pilocarpine from an agonist into an antagonist. J Pharmacol Exp Ther 301: 720-728.